Ameriprise’s Centessa Pharmaceuticals CNTA Stock Holding History

Ameriprise’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-16,893	Closed	-$671K	–	4124
2026 Q1	$671K	Sell	16,893 -263,227	-94%	-$6.73M	﹤0.01%	3467
2025 Q4	$7.01M	Buy	280,120 +172,118	+159%	+$4.36M	﹤0.01%	2188
2025 Q3	$2.62M	Buy	+108,002	New	+$1.92M	﹤0.01%	2866
2025 Q2	–	Sell	-40,868	Closed	-$588K	–	3988
2025 Q1	$588K	Buy	40,868 +21,746	+114%	+$356K	﹤0.01%	3424
2024 Q4	$320K	Buy	+19,122	New	+$317K	﹤0.01%	3697

Ameriprise's CNTA Position: Q2 2026 in Review

Ameriprise sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 16,893 shares — an estimated $671K sold.

Ameriprise first reported a position in CNTA in Q4 2024 and held it in 5 quarters. The position peaked at $7.01M in Q4 2025. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Ameriprise reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Ameriprise sold 16,893 Centessa Pharmaceuticals shares in Q2 2026, an estimated $671K.
Ameriprise first reported a position in Centessa Pharmaceuticals in Q4 2024 and held it in 5 quarters.
Ameriprise's Centessa Pharmaceuticals position peaked at $7.01M in Q4 2025.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.